Clinical Research Directory

Inclusion Criteria: * Participant must be 18 years of age or older, at the time of signing the informed consent * Confirmed diagnosis of CRSwNP for at least 12 months prior to routine care visit 1 * Participants who will be enrolled after index date need to have at least SNOT-22 prior (maximum of 4 weeks) to index date * Documented SNOT-22 total score\>=30, collected within the 4 weeks prior to the first tezepelumab dose (index date) * Treated per the Japanese Handbook for the Management of Chronic Rhinosinusitis with Nasal Polyps for at least 30 days prior to routine care visit 1 * Physician decision that participant is eligible for treatment with tezepelumab according to local approved CRSwNP label and Optimal Clinical Use Guidelines * Patients must be able and willing to read and comprehend written instructions, to collect PROs and medication intake and to sign the informed consent document Exclusion Criteria: * Patients who participate in an interventional clinical trial in the last 4 months * Known hypersensitivity to tezepelumab or any of its excipients * Patients who have received any biologic therapy for asthma or CRSwNP * Condition (acute or chronic) that, in the investigator's opinion, would limit the participant´s ability to complete questionnaires or participate in this study * Pregnancy or lactation period or planning pregnancy during the study period